相关实验视频
Updated: Jun 3, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
FAS和NF-κB信号调节肺癌对突变EGFR的依赖性
Trever G Bivona1, Haley Hieronymus, Joel Parker
1Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20, New York, New York 10065, USA.
核因子-kappa B (NF-κB) 途径的抑制增强了EGFR氨酸激酶抑制剂 (TKI) 在EGFR突变肺癌中的疗效. 与EGFR一起准NF-κB可能会改善肺腺癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 在表皮生长因子受体 (EGFR) 激活突变驱动肺腺癌,但对EGFR氨酸激酶抑制剂 (TKI) 的反应是可变的.
- 瘤细胞对突变EGFR的依赖性可以通过遗传因素调节,从而影响TKI治疗的疗效.
研究的目的:
- 确定影响EGFR突变肺癌细胞对EGFR TKI敏感性的基因修饰剂.
- 研究NF-κB途径在调节TKI治疗反应和耐药性的作用.
主要方法:
- 一个聚合的RNA干扰屏幕被用来识别增强TKI诱导细胞死亡的基因.
- 通过遗传 (敲击,过度表达,沉默) 和药理方法操纵NF-κB通路组件.
- 对患者数据的分析将IκB表达与TKI治疗反应和生存相关联.
主要成果:
- 击败FAS和NF-κB途径组件使EGFR突变肺癌细胞对erlotinib敏感.
- 激活NF-κB会对EGFRTKI产生抗性,而其抑制会增强erlotinib诱导的亡.
- 患者的IκB表达增加预测了对EGFR TKI治疗的更好的反应和生存率.
结论:
- NF-κB通路是肺癌中对EGFR TKI的敏感性和耐药性的关键调节者.
- 与EGFR TKIs同时抑制NF-κB代表了对EGFR突变肺癌的有前途的治疗策略.
- 了解NF-κB的作用可以了解瘤基因依赖和脱离的机制.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
相关概念视频
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...